Animal Facility (AF) Basic and translational cancer investigations at the UPMC Hillman Cancer Center (HCC) are broadly focused on molecular understanding of cancer progression and development of novel preventatives and therapeutics (pharmacological agents, cell-based, and gene therapies) using in vitro and in vivo models of various cancers. Understanding biological processes from single molecule to whole animal is critical, and the Animal Facility (AF) is an essential shared resource charged with educating investigators and providing resources, expertise, and services when these scientific investigations require animal modeling. When new chemotherapeutic agents, diagnostic modalities, or preventive measures show promise using in vitro or theoretical methodologies, a key basic to translational step is use of animal models. This is often required prior to clinical evaluations. For development and testing of cancer prevention or treatment approaches, animal studies may be required to characterize the tumor responsiveness, survival curves, histopathologic changes, and discovery and validation of mechanistic biomarkers. Animal studies allow research teams to study the effectiveness of an intervention by measuring decreases in tumor burden or recruitment of immune effector cells to the tumor microenvironment in vivo. The AF provides investigators across all research programs access to healthy animals (mice, rats and musk shrews), transgenic strains, appropriate husbandry, veterinary support, veterinary pathologist expertise and novel dedicated equipment under barrier conditions (e.g., gamma irradiators, imaging devices) that allow multi-parametric and quantitative analyses of events in vivo in a highly reproducible manner and with efficiency.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-32
Application #
10024337
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-09-10
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
32
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478

Showing the most recent 10 out of 1187 publications